Here are relevant reports on : respiratory-drugs-market
-
Medical Device Connectivity Market by Product & Services, Technology, Application (Vital Signs & Patient Monitors, Ventilators, Anesthesia Machines, Infusion Pumps, Imaging Systems, Respiratory devices), End User, and Region - Global Forecast to 2028
The global medical device connectivity market, valued at US$2.1 billion in 2022, stood at US$2.6 billion in 2023 and is projected to advance at a resilient CAGR of 21.5% from 2023 to 2028, culminating in a forecasted valuation of US$7.4 billion by the end of the period. This growth is driven by factors such as healthcare provider consolidations, telehealth expansion, and increasing home healthcare preferences.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Future combat uniforms/Body Amour & Personal Protective Equipment Market (PPE)(Above neck, Protective Clothing, Respiratory Protective Equipment, Gloves & Footware) - 2019 By Geography
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030
The global patient derived xenografts/PDX models market, valued at US$0.32 billion in 2024, stood at US$0.37 billion in 2025 and is projected to advance at a resilient CAGR of 12.5% from 2025 to 2030, culminating in a forecasted valuation of US$0.66 billion by the end of the period. The major factors driving the growth in the PDX model market include the rising demand for clinically relevant preclinical models that closely replicate human tumor biology and therapeutic response.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
CBRN Defense Market by Type (Chemical, Biological, Radiological, Nuclear, Explosives), Equipment (Protective Wearables, Respiratory Systems, Detection & Monitoring Systems, Decontamination Systems, Simulators, Others), End Use and Region - Global Forecast to 2028
The CBRN Defense market is expected to grow from USD 16.1 billion in 2023 to USD 21.4 billion by 2028, at a compound annual growth rate (CAGR) of 5.8 % during the forecast period. The key players Rheinmetall Defence (Germany), Thales Group (France), Smiths Group PLC (UK), Teledyne FLIR LLC (US), Bruker Corporation (US).
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030
The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$26.28 billion by the end of the period.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
mRNA Therapeutics Market by Product (Vaccines, Drugs), Application (Oncology, Rare Diseases, Infectious Diseases, Other Applications), End User (Hospitals & Clinics, Research Settings) - Global Forecast to 2027
The global mRNA therapeutics market is projected to reach USD ~35 billion by 2027 from USD 32 billion in 2022, at a CAGR of ~2% between 2022 and 2027.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The global age-related macular degeneration (AMD) drugs market, valued at US$9.55 billion in 2023, stood at US$10.46 billion in 2024 and is projected to advance at a resilient CAGR of 10.7% from 2024 to 2029, culminating in a forecasted valuation of US$17.37 billion by the end of the period. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Rotator Cuff Injury Treatment Market by Modality (Surgical (Arthroscopy, Shoulder Replacement, Tendon Repair), Physiotherapy (Braces, Cold Compression), Drug Therapeutics (Anti-inflammatory Drugs, Injections), Orthobiologics) - Global Forecast to 2026
The global rotator cuff injury treatment market growth is primed to transition from $989.3 million in 2021 to $1,244.2 million by 2026, showcasing a strong CAGR of 4.7%. The key factors fueling the growth of this market include an increase in sports-related shoulder injuries, technological advancements in arthroscopic surgical devices, increase in aging population with osteoarthritis, strong focus of players towards launch of highly advanced arthroscopic treatment devices.
- Published: April 2022
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Oligonucleotide Synthesis Market by Product {Drugs [ASO, siRNA], Synthesized Oligos [Product (Primers, Probes), Type (Custom, Predesigned)], Reagents, Equipment}, Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Asia Pacific Oligonucleotide Synthesis market, valued at USD 1.76 billion in 2024, stood at USD 2.08 billion in 2025 and is projected to advance at a resilient CAGR of 18.5% from 2025 to 2030, culminating in a forecasted valuation of USD 4.88 billion by the end of the period. This expansion is driven by increasing demand from therapeutics, diagnostics, and research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
